EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL

被引：0
|
作者：
Ferreira, Carlos G. [1 ]
Barrios, C. [2 ]
Shaw, Alice T. [3 ]
Shi, Yuankai [4 ]
De Pas, Tommaso M. [5 ]
Yang, Pan C. [6 ]
Riely, Greg J. [7 ]
Crino, Lucio [8 ]
Iyer, Shrividya [9 ]
Polli, Anna [11 ]
Lanzalone, Silvana [11 ]
Kim, Dong W. [10 ]
机构：
[1] Inst Nacl Canc, Div Clin & Translat Res, Rio De Janeiro, Brazil
[2] Pucrs Sch Med, Dept Med, Porto Alegre, RS, Brazil
[3] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[4] Chinese Acad Med Sci Cams, Dept Med Oncol, Beijing, Peoples R China
[5] European Inst Oncol, Med Oncol Unit Resp Tract & Sarcomas, Milan, Italy
[6] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] S Maria Della Misericordia Hosp, Perugia, Italy
[9] Pfizer, Oncol, New York, NY USA
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[11] Pfizer, Oncol, Milan, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S107 / S108
页数：2
相关论文
共 50 条
  • [31] Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC)
    Tan, Weiwei
    Wilner, Keith D.
    Lanzalone, Silvana
    Polli, Anna
    Zierhut, Matthew L.
    Nickens, Dana
    O'Byrne, Kenneth J.
    Blackhall, Fiona H.
    Shaw, Alice T.
    Salgia, Ravi
    Jaime, Jesus Correl
    Kim, Dong-Wan
    CANCER RESEARCH, 2015, 75
  • [32] Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
    Kilickap, S.
    Ozturk, A.
    Karadurmus, N.
    Korkmaz, T.
    Yumuk, P.
    Cicin, I.
    Paydas, S.
    Cilbir, E.
    Sakalar, T.
    Uysal, M.
    Uskent, N.
    Demir, N.
    Sakin, A.
    Turhal, N.
    Keskin, S.
    Tural, D.
    Eralp, Y.
    Basal, F.
    Yasar, H.
    Sendur, M. A.
    Demirci, U.
    Cubukcu, E.
    Karaagac, M.
    Karaca, S.
    Tatli, A.
    Yetisyigit, T.
    Urvay, S.
    Gursoy, P.
    Uluc, B. Oyan
    Turna, Z.
    Kucukoner, M.
    Olmez, O.
    Cabuk, D.
    Seker, M.
    Unal, O.
    Meydan, N.
    Okutur, S.
    Tunali, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S477 - S478
  • [33] Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer
    Watanabe, S.
    Matsumoto, N.
    Koshio, J.
    Ishida, A.
    Tanaka, T.
    Abe, T.
    Ishikawa, D.
    Shoji, S.
    Nozaki, K.
    Ichikawa, K.
    Kondo, R.
    Otsubo, A.
    Aoki, A.
    Kajiwara, T.
    Koyama, K.
    Miura, S.
    Yoshizawa, H.
    Kikuchi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S336 - S336
  • [34] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
    Camidge, D. Ross
    Bang, Yung-Jue
    Kwak, Eunice L.
    Iafrate, A. John
    Varella-Garcia, Marileila
    Fox, Stephen B.
    Riely, Gregory J.
    Solomon, Benjamin
    Ou, Sai-Hong I.
    Kim, Dong-Wan
    Salgia, Ravi
    Fidias, Panagiotis
    Engelman, Jeffrey A.
    Gandhi, Leena
    Jaenne, Pasi A.
    Costa, Daniel B.
    Shapiro, Geoffrey I.
    LoRusso, Patricia
    Ruffner, Katherine
    Stephenson, Patricia
    Tang, Yiyun
    Wilner, Keith
    Clark, Jeffrey W.
    Shaw, Alice T.
    LANCET ONCOLOGY, 2012, 13 (10): : 1011 - 1019
  • [35] Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Vizcarrondo, F. R.
    Patel, S. P.
    Pennell, N. A.
    Pakkala, S.
    West, H.
    Kratzke, R.
    Tarazi, J.
    Wilner, K.
    Polli, A.
    Tan, W.
    Liu, Y.
    Valota, O.
    Piperdi, B.
    Reckamp, K. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Biagio Ricciuti
    Andrea De Giglio
    Carmen Mecca
    Cataldo Arcuri
    Sabrina Marini
    Giulio Metro
    Sara Baglivo
    Angelo Sidoni
    Guido Bellezza
    Lucio Crinò
    Rita Chiari
    Medical Oncology, 2018, 35
  • [37] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
  • [38] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Ricciuti, Biagio
    De Giglio, Andrea
    Mecca, Carmen
    Arcuri, Cataldo
    Marini, Sabrina
    Metro, Giulio
    Baglivo, Sara
    Sidoni, Angelo
    Bellezza, Guido
    Crino, Lucio
    Chiari, Rita
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [39] Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non-Small Cell Lung Cancer?
    Crystal, Adam S.
    Shaw, Alice T.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4479 - 4481
  • [40] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
12345